Showing results (151-160 of 179) with videos related to

Sort By:
Pageof 18
Japanese Journal of Clinical Oncology|January 8, 2025
Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113Koh Fukushi, Hiroshi Imaoka, Masafumi Ikeda, et al.
Cancer Chemotherapy and Pharmacology|January 18, 2012
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)Masato Ozaka, Yuji Matsumura, Hiroshi Ishii, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|October 12, 2024
Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinomaYuki Hirose, Atsushi Oba, Manabu Takamatsu, et al.
British Journal of Clinical Pharmacology|June 1, 2026
Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT studyTakashi Yokokawa, Daiki Tsuji, Masahiro Hatori, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|September 4, 2025
Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity score-matched analysisNaohiro Okano, Kentaro Sakamaki, Takafumi Mie, et al.
Cancer Medicine|February 26, 2021
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapyMakoto Ueno, Chigusa Morizane, Masayuki Furukawa, et al.
Journal of Surgical Oncology|January 27, 2026
Original Study: Risk Factors for Early Recurrence in Patients With Biliary Tract Cancers Who Underwent Curative Resection: An Exploratory Subgroup Analysis of JCOG1202Hiroaki Yanagimoto, Kohei Nakachi, Masafumi Ikeda, et al.
The Oncologist|August 2, 2023
Early Tumor Shrinkage and Depth of Response as Predictors of Survival for Advanced Biliary Tract Cancer: An Exploratory Analysis of JCOG1113Naohiro Okano, Chigusa Morizane, Takuji Okusaka, et al.
Cancer Research Communications|February 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 StudyStephen L Chan, Thomas Yau, Robin K Kelley, et al.
Lancet (London, England)|April 19, 2023
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.
Pageof 18